ArticleMaterials today. Bio2025
Design, optimization, and evaluation of lyophilized lipid nanoparticles for mRNA-based pulmonary mucosal vaccination.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Cholesterol analogs modulate lipid nanoparticle performance for mRNA delivery after lyophilization and enable ocular disease therapy.Materials today. Bio · 2026Article
- An intramuscular prime-intranasal boost strategy for mRNA-LNP vaccine induces mucosal immune response against SARS-CoV-2 in murine model.Journal of translational medicine · 2026Article
- Immune Modulatory Oxysterols Produced from Cholesterol-Containing Lipid Nanoparticles Regulate Tumor Growth.ACS nano · 2026Article
- Development of hesperidin loaded lipid-chitosan nanoparticles: physicochemical characterization, molecular docking and ex vivo study.Scientific reports · 2026Article
- Freeze-Drying in Sucrose Followed by Cryomilling Enables the Formulation of sa-mRNA-LNP Powders for Inhalation.Pharmaceutics · 2026Article
- Nanotechnology-Enhanced Vaccines for Respiratory Infections: Opportunities and Challenges.International journal of nanomedicine · 2026Review
- Lipid nanoparticle-based mRNA platforms for mucosal HIV vaccines: formulation advances, immune mechanisms, and translational pathways.Archives of microbiology · 2025Review
- Tomatine as a versatile adjuvant boosts mRNA vaccine responses.Materials today. Bio · 2025Article
- Dorsal root ganglion-targeted analgesic delivery for effective relief of neuropathic pain.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid nanoparticles (LNP) have emerged at the forefront of the delivery of RNA molecules during the COVID-19 pandemic, leading to a giant leap in RNA therapies. Despite their great success, the long-term storage and transportation of mRNA vaccines without ultra-low temperatures is still challenging due to their poor stability. Here, we demonstrated that LNP-mRNA could be lyophilized via a simple freeze‒drying process. This process produced a dry powder formulation that could maintain the physicochemical properties of LNP-mRNA after storage at 4 °C for at least two months. However, the shear forces generated during the lyophilization process may disrupt the structure of the LNP, affecting the efficacy of the vaccine. Therefore, a cholesterol analogue, β-sitosterol, and a type of phospholipid, DOPE, were utilized instead of cholesterol and DSPC to improve the transfection efficiency after freeze-drying. The optimized formulation of LNP exhibited an enhanced transfection effect both
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.